Lavior Pharma Appoints Dr. Imaze Marian Davis as Chief Medical Officer
"
"Her track record in reducing amputations through innovative protocols and her passion for mentoring future physicians align perfectly with our mission," added
Born in
A diplomate of both the American Board of Multiple Specialties in Podiatry and the American Board of Podiatric Medicine, she holds certifications in primary care podiatric medicine, podiatric surgery, minimally invasive surgery, and is a Certified Wound Specialist Physician. She has also participated in advanced wound-care surgical training programs with North Shore Medical Center, Jackson Health System, Hialeah Hospital, and Aventura Hospital.
Elected to the ABPM Board in 2023,
"I am honored to join Lavior Pharma at such an exciting time," said
About Lavior Pharma Inc.
Lavior Pharma Inc. is a woman-owned pharmaceutical company focused on first-in-class therapies for complex, underserved conditions—especially diabetic foot ulcers and chronic wounds. Our mission is to leverage cutting-edge science and inclusive leadership to transform patient care. For more information, visit www.lavior.com or follow us on social media (@LaviorPharma).
Media Contact:
Co-Founder and COO, Lavior Pharma Inc.
305-627-3680 • [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/lavior-pharma-appoints-dr-imaze-marian-davis-as-chief-medical-officer-302495203.html
SOURCE Lavior
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management
- HIS HIGHNESS SHAIKH KHALED ALQASSIMI ANNOUNCES SUPPORT FOR LEMLOANS AS DECENTRALIZED LENDING PROTOCOL EXPANDS ITS GLOBAL ROADMAP
- Encrypted Phone Vault Vaultaire Makes Client-Side Cloud Backup Free for Every User
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share